SCHEMBL378670

SCHEMBL378670

CC(C)CC1(C(=O)O)CCN(C(=O)c2ccc(-c3ccc(F)cc3)cc2)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.54
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
SLC6A7 Q99884 2/20 0.49
HSD11B1 P28845 1/20 0.47
PTGER2 P43116 3/20 0.44
PTGER4 P35408 1/20 0.44
PTGDR Q13258 1/20 0.44
PTPN1 P18031 1/20 0.44
DRD1 P21728 1/20 0.43
HRH4 Q9H3N8 1/20 0.43
CYP2D6 P10635 1/20 0.43
NQO2 P16083 1/20 0.43
PDE3B Q13370 1/20 0.43
PDE3A Q14432 1/20 0.43
LTB4R Q15722 1/20 0.43
PTGDR2 Q9Y5Y4 1/20 0.43
AGTR2 P50052 1/20 0.43
HPGD P15428 1/20 0.43
MAPK1 P28482 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL378819 0.85 PKLR (0.53) POLBMEN1KMT2ASLC6A7
SCHEMBL13092320 0.83 POLB (0.47) POLBMEN1KMT2ASLC6A7HSD11B1
SCHEMBL3087329 0.83 SLC6A7 (0.49) POLBMEN1KMT2ASLC6A7HSD11B1
SCHEMBL379026 0.81 HSD11B1 (0.51) POLBMEN1KMT2ASLC6A7HSD11B1
SCHEMBL378365 0.81 HSD11B1 (0.53) MEN1KMT2ASLC6A7HSD11B1PTPN1
SCHEMBL378643 0.79 HSD11B1 (0.51) MEN1KMT2ASLC6A7HSD11B1PTPN1
SCHEMBL21166248 0.79 SLC6A7 (0.57) POLBMEN1KMT2ASLC6A7HSD11B1
SCHEMBL3098857 0.77 MEN1 (0.48) POLBMEN1KMT2A
SCHEMBL8160260 0.76 SLC6A7 (0.57) POLBMEN1KMT2ASLC6A7HSD11B1
SCHEMBL2702158 0.76 KMT2A (0.50) MEN1KMT2ASLC6A7HSD11B1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
EP-2408745-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS F. Hoffmann-La Roche AG (CH) 2012-01-25 EP disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
WO-2010106081-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-09-23 WO disclosed
WO-2010106081-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HTR3A, OPRL1, OPRK1 POLB 2329/4885MEN1 4869/4885KMT2A 1488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.